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Escherichia coli and Klebsiella pneumoniae are frequently found resistance to
aminoglycosides in Turkey. The aim of this study was to investigate aminoglycoside
resistance in clinical isolates of E. coli and K. pneumoniae from Turkey using both
phenotypic and genotypic methods and screening for the prevalence of gene coding for
common aminoglycoside-modifying enzymes (AMEs) and 16S rRNA methylase
genes. A total of 88 consecutive, non-duplicated E. coli (n= 65) and K. pneumoniae
(n= 23) isolates showing resistance or intermediate resistance to amikacin and/or
gentamicin were collected between October 2013 and May 2015 from clinical samples
received at Gaziantep Dr. Ersin Arslan Training and Research Hospital. Seventeen
isolates were obtained from Syrian patients. Isolates resistant to any of the two
aminoglycosides were tested by PCR for seven AME genes, and 22 isolates with
amikacin MIC≥16 mg/L were also tested for 16S rRNA methylase genes. In E. coli
isolates, the most frequent genes were aac(6′)-Ib (50 strains; 76.9%) and aac(3)-IIa
(40 strains; 70.7%), followed by aph(3′)-Ia (5 strains; 7.6%) and ant(2″)-Ia (2 strains;
3.1%). Among the 23 resistant K. pneumoniae isolates, the most prevalent gene was
aac(3′)-IIa (87.0%) followed by aac(6′)-Ib (73.9%) and aph(3′)-Ia (8.6%). The rmtC
gene was detected in one K. pneumoniae isolate. Resistance to aminoglycosides in
clinical isolates of E. coli and K. pneumoniae from our center is predominantly caused
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by AAC(6′)-Ib and AAC(3)-II enzymes, while the occurrence of 16S rRNA methy-
lases is so far limited.
Keywords: aminoglycoside-modifying enzyme, 16S rRNA methyltransferase,
E. coli, K. pneumoniae
Introduction
Aminoglycosides are a large family of drugs that act at the ribosome by
inhibiting one or more of the biochemical steps involved in translation. They are
extensively used in the treatment of serious bacterial infections, particularly in
combination with β-lactams or glycopeptides [1]. The increasing problem of
multiresistance in Gram-negative bacteria and the introduction of new aminogly-
coside analogues (e.g., plazomicin) warrant new studies aimed at understanding
aminoglycoside resistance [2].
According to the Central Asian and Eastern European Survillance of
Antimicrobial Resistance (CAESAR) annual report 2016, Escherichia coli and
Klebsiella pneumoniae had high resistance to the third-generation cephalosporins,
aminoglycosides, and fluoroquinolones in Turkey [3].
In terms of frequency, the most important determinant of aminoglycoside
resistance in E. coli, K. pneumoniae, and many other Gram-negative bacteria is
aminoglycoside-modifying enzymes (AMEs), of which three classes are defined
according to their modifying activities: acetyltransferases (AAC), nucleotidyl-
transferases (ANT), and phosphotransferases (APH) [4]. Other mechanisms
conferring aminoglycoside resistance include active efflux of the antimicrobial
and reduced intake into the bacterial cell, and production of several 16S rRNA
methylases with ArmA, RmtB, and RmtC being the most widespread [2, 5].
Genes encoding AMEs and 16S rRNA methylases are located on mobile
genetic elements along with other resistance determinants, such as extended-
spectrum β-lactamases (ESBLs) and carbapenemases, contributing to explain
multidrug resistance in clinical isolates [6].
The aim of this study was to investigate aminoglycoside resistance in E. coli
and K. pneumoniae using both phenotypic and genotypic methods.
Materials and Methods
Bacterial isolates
A total of 88 consecutive, non-duplicated E. coli and K. pneumoniae isolates
collected from clinical samples between October 2013 and May 2015 at Gaziantep
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Dr. Ersin Arslan Training and Research Hospital and showing resistance or
decreased susceptibiliy to amikacin and/or gentamicin were studied. Seventeen
isolates were from Syrian patients (9 K. pneumoniae and 8 E. coli).
Antimicrobial susceptibility testing
The strains were identified by both conventional methods and Vitek 2
Compact system (BioMérieux, France). Antibiotic susceptibility (aminoglycosides,
carbapenems, and ciprofloxacin) and ESBL production of isolates were tested by the
Vitek 2 Compact system. The isolates were selected based on Vitek 2 results. In
addition, the disk diffusion method was also performed for amikacin, gentamicin,
and tobramycin. The results were interpreted using clinical breakpoints as defined
by the Clinical Laboratory and Standards Institute [7]. E. coli ATCC 25922 and
Pseudomonas aeruginosa ATCC 27853 were used as quality control strains.
Molecular characterization of aminoglycoside resistance genes
Isolates resistant to any of the indicated aminoglycosides were tested by
PCR for seven AME genes. Twenty-two isolates (19 E. coli and 3 K. pneumoniae)
with a minimum inhibitory concentration (MIC) of amikacin ≥16 mg/L were also
tested for 16S rRNA methylase genes. As a control, 10 isolates susceptible to the
indicated aminoglycosides were also used in the PCR analysis. Sets of primers for
the following genes were included in the PCR assay: aac(3)-Ia, aac(3)-IIa,
aac(6)-Ib, ant(2)-Ia, aph(3)-Ia, aph(3)-IIa, aph(3)-Via, armA, rmtB, rmtC, and
rmtD. The primers for AME and methyltransferase genes and their expected
amplicon sizes are shown in Tables I and II.
Genomic DNA was extracted using an InstaGeneTM Matrix Kit (Bio-Rad,
Madrid, Spain) according to the manufacturer’s instructions. Then, 2 μl of DNA
were added to a reaction mixture containing 1× PCR buffer, 1.5 mM MgCl2,
200 μM deoxynucleoside triphosphate, 0.5 μM of each primer, and 1 U of Taq
DNA Polymerase (Bioline, London, UK). Amplification conditions were 94 °C for
5 min, followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s [60 °C for aac(6)-Ib]
and 72 °C for 1 min, and a final elongation at 72 °C for 10 min. PCR products were
analyzed on 1.5% (w/v) agarose gels stained with ethidium bromide.
Results
Thirty-three (50.7%) E. coli isolates were resistant to amikacin by Vitek 2
compared to 25 (38.4%) by disk diffusion. Eight (34.7%) K. pneumoniae isolates
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were resistant to amikacin by Vitek 2 compared to 13 (56.5%) by the disk
diffusion. Resistance to gentamicin among E. coli and K. pneumoniae was similar
by disk diffusion and Vitek 2 [47 isolates each (72.3%) and 21 isolates each
(91.3%), respectively]. Resistance of E. coli and K. pneumoniae to tobramycin, as
defined by disk diffusion, was 100% and 93.8%, respectively (Table III). Resis-
tance rates of E. coli and K. pneumoniae to carbapenems and ciprofloxacin are also
shown in Table IV. Fifty-six (86.1%) E. coli and 22 (95.6%) K. pneumoniae
isolates were found positive for ESBL production.
Overall, the most frequent genes were aac(6′)-Ib (67 strains; 76.1%) and
aac(3)-IIa (66 strains; 75.0%), followed by aph(3′)-Ia (7 strains; 8.0%) and ant
(2″)-Ia (2 strains; 2.3%). Among the isolates from Syrian patients (17 strains), the
Table I. Primers used in the detection of aminoglycoside-modifying enzyme (AME) and expected
amplicon sizes
Gene DNA sequence (5′–3′) Product (bp) Reference
aac(6′)-Ib aac6′-Ib-F TTGCGATGCTCTATGAGTGGCTA 482 [8]
aac6′-Ib-R CTCGAATGCCTGGCGTGTTT
aac(3)-IIa aac3-IIa-F GGCAATAACGGAGGCGCTTCAAAA 563 [1]
aac3-IIa-R TTCCAGGCATCGGCATCTCATACG
aac(3)-Ia aac3-Ia-F GCAGTCGCCCCTAAAACAAA 464 [1]
aac3-Ia-R CACTTCTTCCCGTATGCCCAACTT
aph(3′)-VIa aph3′-VIa-F AAAGCGATCAATGCAAAACC 310 [1]
aph3′-VIa-R TATCCGTGATATCGCCATGA
ant(2″)-Ia ant2″-Ia-F CGTCATGGAGGAGTTGGACT 303 [1]
ant2″-Ia-R CGCAAGACCTCAACCTTTTC
aph(3′)-Ia ant2″-Ia-F CGAGCATCAAATGAAACTGC 624 [1]
ant2″-Ia-R GCGTTGCCAATGATGTTACAG
aph(3′)-IIa aph3′-Ia-F GAACAAGATGGATTGCACGC 680 [1]
aph3′-Ia-R GCTCTTCAGCAATATCACGG
Table II. Primers used in the detection of methyltransferase genes and expected amplicon sizes
Gene DNA sequence (5′–3′) Product (bp) Reference
armA armA-F CAAATGGATAAGAATGATGTT 777 [9]
armA-R TTATTTCTGAAATCCACT
rmtB rmtB-F TCAACGATGCCCTCACCTC 459 [10]
rmtB-R GCAGGGCAAAGGTAAAATCC
rmtC rmtC-F CGAAGAAGTAACAGCCAAAG 711 [11]
rmtC-R ATCCCAACATCTCTCCCACT
rmtD rmtD-F GAGCGAACTGAAGGAAAAAC 730 [12]
rmtD-R CAGCACGTAAAACAGCTC
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most prevalent gene was aac(3)-IIa (82.3%), followed by aac(6′)-Ib (64.7%) and
aph(3′)-Ia (5.8%).
The most frequent AME gene in 65 resistant E. coli isolates was aac(6′)-Ib,
identified in 50 (76.9%) isolates, followed by aac(3)-IIa in 46 (70.7%) isolates,
aph(3′)-Ia in 5 (7.6%), and ant(2″)-Ia in 2 (3.1%) isolates. The genes aac(3)-Ia,
aph(3′)-VIa, and aph(3′)-IIa were not found in E. coli isolates. Among the 23
resistant K. pneumoniae isolates, the prevalence of AME genes was as follows:
aac(3)-IIa was the most frequent one, identified in 20 (87.0%) isolates, followed by
aac(6′)-Ib in 17 (73.9%) isolates and aph(3′)-Ia in 2 (8.6%). The genes aac(3)-Ia,
aph(3′)-VIa, aph(3′)-IIa, and ant(2″)-Ia were not found in K. pneumoniae isolates.
In three (one K. pneumoniae and two E. coli) isolates, none of the seven
investigated AME genes was detected. One of those E. coli isolates had an
intermediate category to gentamicin by Vitek 2 but was susceptible to that agent
by disk diffusion. The other E. coli isolate was resistant to all tested aminoglyco-
sides. We detected the rmtC gene in the K. pneumoniae isolate.
Fifty-five isolates were presented with more than one gene. The combination
of aac(6′)-Ib and aac(3)-IIa was the most common one for both E. coli (33
isolates; 51%) and K. pneumoniae (14 isolates; 61%) isolates, followed by
aac(3)-IIa and aph(3′)-Ia in E. coli (5 isolates; 6%) and K. pneumoniae (1 isolate;
4.3%). One E. coli isolate harbored four genes: aac(6′)-Ib+ aac(3)-IIa+aph(3′)-Ia
Table III. The resistance rates of aminoglycosides in E. coli and K. pneumoniae isolates
E. coli K. pneumoniae
Disk diffusion Vitek 2 Disk diffusion Vitek 2
Amikacin 50.7 38.4 34.7 56.5
Gentamicin 72.3 72.3 91.3 91.3
Tobramycin 93.8 ND 100 ND
Note: ND: non-detected.
Table IV. The antimicrobial resistance rates of carbapenems, ciprofloxacin, and ESBL production of E. coli
and K. pneumoniae isolates by Vitek 2 method
E. coli K. pneumoniae
ESBL 86.1 95.6
Imipenem 4.6 17.3
Meropenem 4.6 17.3
Ertapenem 9.2 26.0
Ciprofloxacin 96.9 69.5
Note: ESBL: extended-spectrum β-lactamase.
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+ant(2″)-Ia. One K. pneumoniae isolate harbored three genes: aac(6′)-Ib+
aac(3)-IIa+ aph(3′)-Ia.
Discussion
According to the CAESAR annual report 2016, the percentage of amino-
glycoside (amikacin, gentamicin, and tobramycin) resistance was 29% for E. coli
and 45% for K. pneumoniae among blood and cerebrospinal fluid isolates in
Turkey in 2014 [3].
In this study, a total of 72.3% and 50.7% of the E. coli isolates were resistant
or intermediate to gentamicin and amikacin by Vitek 2. For K. pneumonia, the
prevalence of resistance was 91.3% and 34.7% to gentamicin and amikacin,
respectively. In both E. coli and K. pneumoniae, the prevalence of reduced
susceptibility was higher for tobramycin.
The finding of this study that the most frequent AME genes were aac(6′)-Ib
followed by aac(3)-IIa, aph(3′)-Ia, and ant(2″)-Ia is in line with a Spanish study,
in which the most prevalent AME genes in 420 ESBL-positive E. coli and 139
ESBL-positive K. pneumoniae were aac(6′)-Ib (16.2% and 44.6%, respectively)
and aac(3)-IIa (14.7% and 43.1%, respectively) [13]. In an another Spanish study,
including 257 E. coli isolates resistant to amoxicillin/clavulanic acid, the most
prevalent AME genes were aac(6′)-Ib followed by aph(3′)-Ia, ant(2″)-Ia, and
aac(3′)-IIa(2). However, in a study from Norway, PCR screening for AME genes
showed that the most prevalent AME gene in both E. coli and K. pneumoniae was
aac(3)-II, followed by aac(6′)-Ib, whereas ant(2″)-Ia was only identified in three
E. coli isolates [6].
The aac(6′)-Ib gene, which is probably the most clinically relevant AAC in
Enterobacteriaceae, is responsible for resistance to amikacin and tobramycin, but
not gentamicin [4]. In this study, 17 out of the 18 (94.4%) isolates that were only
positive for aac(6′)-Ib expressed phenotypic resistance to amikacin. Among the
isolates with the aac(6′)-Ib gene, the prevalence of ESBL production and
ciprofloxacin resistance was 91% and 94%, respectively. This finding supports
the fact that the aac(6′)-Ib gene is usually associated with quinolone resistance
genes or β-lactamase genes [4]. In another study in Turkey, the authors indicated
that an aac(6′)-IV enzyme, presumably related to AAC(6′)-Ib, was the most
common AME in Klebsiella spp. (37.5%), whereas AAC(3)-II were the most
common one (58%) in E. coli [14]. Resistance to aminoglycosides in 16 ESBL-
producing Enterobactericeae isolated in a Turkish hospital was explained by the
presence of the aac(3)-II and the aac(6′)-Ib-cr genes. Four of those isolates
harbored an additional aph(3′)-I gene [15].
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In this study, the second most common AME gene was aac(3)-IIa, which
causes resistance to gentamicin, netilmicin, and tobramycin [4]. In the isolates
containing this gene, resistance rates to gentamicin (95.4% with MICs≥ 16 mg/L)
and tobramycin (96.9%) are in agreement with the expected phenotype. In
addition, eight isolates (9%) harboring aph(3′)-Ia co-harbored the aac(3′)-IIa
gene, and were resistant to gentamicin. The APH(3′)-I subclass shows a
resistance profile including kanamycin and neomycin and is widely distributed
among Gram-negative bacteria containing wide host range plasmids and
transposons [4].
ANT(2″)-Ia is also commonly encoded by plasmids and transposons and
mediates resistance to gentamicin, tobramycin, and kanamycin [4]. We found the
ant(2″)-Ia gene in only two E. coli isolates, which were resistant to both
gentamicin and tobramycin.
Among the Syrian patients (n= 17), the most prevalent gene was aac(3)-IIa
(82.3%), followed by aac(6′)-Ib (64.7%) and aph(3′)-Ia (5.8%). The most frequent
association was aac(3)-IIa and aac(6′)-Ib (52.9%). To the best of our knowledge,
this is the first report of AMEs resistance from Syrian patients in Turkey.
K. pneumoniae and P. aeruginosa showing high-level resistance to clini-
cally useful aminoglycosides through the production of acquired methyltrans-
ferases were identified in France and Japan, respectively, in 2003 [9, 16]. These
enzymes are mostly located on transferable plasmids, and could be easily
transferred to other bacterial species [5]. In this study, the rmtC gene was identified
in a singleK. pneumoniae isolated from a blood culture, which does not harbor any
of the studied AME genes, produce an ESBL, and was also carbapenem-resistant.
MICs of amikacin and gentamicin for this organism are >64 and >16 mg/L,
respectively. In Turkey, the rmtC gene has been previously detected in four
K. pneumoniae isolates resistant to both amikacin (MIC >512 mg/L) and genta-
micin (MIC >128 mg/L) and producing the NDM-1 carbapenemase [17]. The rmtB
gene has also been identified in an aminoglycoside-resistant K. pneumoniae isolate
in Turkey. This represented the first report in Turkey of a clinical isolated with a
single plasmid containing the genes rmtB, qepA, and blaCTX-M-15 [10]. On the
other hand, resistance due to 16S rRNA methyltransferases was not found in
any of 37 aminoglycoside-resistant Turkish clinical isolates with an amikacin
MIC ≥128 [18].
In conclusion, resistance to aminoglycosides in clinical isolates of E. coli
and K. pneumoniae isolated in Gaziantep is predominantly caused by the
AAC(6′)-Ib and the AAC(3)-II enzymes, while the occurrence of 16S rRNA
methylases is so far limited. Further studies are needed to determine the impor-
tance of AMEs and 16S rRNA methyltransferase as causes of aminoglycoside
resistance in Turkey.
AMINOGLYCOSIDE RESISTANCE IN MULTIDRUG-RESISTANT ENTEROBACTERIACEAE 333
Acta Microbiologica et Immunologica Hungarica 66, 2019
Conflict of Interest
The authors declare no conflict of interest.
References
1. Miro´, E., Grünbaum, F., Go´mez, L., Rivera, A., Mirelis, B., Coll, P., Navarro, F.:
Characterization of aminoglycoside-modifying enzymes in Enterobacteriaceae clinical
strains and characterization of the plasmids implicated in their diffusion. Microb Drug
Resist 19, 94–99 (2013).
2. Fernandez-Martınez, M., Miro, E., Ortega, A., Bou, G., Gonzalez-Lopez, J. J., Oliver, A.,
Pascual, A., Cercenado, E., Oteo, J., Martınez-Martınez, L., Navarro, F.: Spanish network
for the research in infectious diseases (REIPI): Molecular identification of aminoglycoside
modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/
clavulanic acid isolated in Spain. Int J Antimicrob Agents 46, 157–163 (2015).
3. http://www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistance/
publications/2016/central-asian-and-eastern-european-surveillance-of-antimicrobial-resistance.
annual-report-2016.
4. Ramirez, M. S., Tolmasky, M. E.: Aminoglycoside modifying enzymes. Drug Resist
Update 13, 151–171 (2010).
5. Wachino, J., Arakawa, Y.: Exogenously acquired 16S rRNA methyltransferases found in
aminoglycoside-resistant pathogenic Gram-negative bacteria: An update. Drug Resist
Updat 15, 133–148 (2012).
6. Haldorsen, B. C., Simonsen, G. S., Sundsfjord, A., Samuelsen, O., Norwegian Study
Group on Aminoglycoside Resistance: Increased prevalence of aminoglycoside resis-
tance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated
with the acquisition of AAC(3)-II and AAC(6¢)-Ib. Diagn Microbiol Infect Dis 78, 66–69
(2014).
7. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Suscepti-
bility Tests for Bacteria that Grow Aerobically; Approved Standard, 9th Edition. Document
M07–A9. CLSI, Wayne, PA, 2012.
8. Park, C. H., Robicsek, A., Jacoby, G. A., Sahm, D., Hooper, D. C.: Prevalence in the United
States of aac(6′)-Ib-cr encoding a ciprofloxacin-modifying enzyme. Antimicrob Agents
Chemother 50, 3953–3955 (2006).
9. Galimand, M., Courvalin, P., Lambert, T.: Plasmid-mediated high-level resistance to
aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents
Chemother 47, 2565–2571 (2003).
10. Fritsche, T. R., Castanheira, M., Miller, G. H., Jones, R. N., Armstrong, E. S.: Detection of
methyltransferases conferring high-level resistance to aminoglycosides in Enterobacter-
iaceae from Europe, North America, and Latin America. Antimicrob Agents Chemother 52,
1843–1845 (2008).
11. Doi, Y., Arakawa, Y.: 16S ribosomal RNA methylation: Emerging resistance mechanism
against aminoglycosides. Clin Infect Dis 45, 88–94 (2007).
334 CIRIT ET AL.
Acta Microbiologica et Immunologica Hungarica 66, 2019
12. Castanheira, M., Fritsche, T. R., Sader, H. S., Jones, R. N.: RmtD 16S RNA methylase in
epidemiologically unrelated SPM-1-producing Pseudomonas aeruginosa isolates from
Brazil. Antimicrob Agents Chemother 52, 1587–1588 (2008).
13. Fernandez-Martinez, M., Ruiz del Castillo, B., Lecea-Cuello, M. J., Rodriguez-Bano, J.,
Pascual, A., Martinez-Martinez, L., Spanish Network for the Research in Infectious
Diseases (REIPI), The Spanish Group for Nosocomial Infections (GEIH): Prevalence of
aminoglycoside-modifying enzymes in Escherichia coli and Klebsiella pneumoniae pro-
ducing extended spectrum β-lactamases collected in two multicenter studies in Spain.
Microb Drug Resist 24, 367–376 (2018).
14. Over, U., Gür, D., Unal, S., Miller, G. H., Aminoglycoside Resistance Study Group: The
changing nature of aminoglycoside resistance mechanisms and prevalence of newly
recognized resistance mechanisms in Turkey. Clin Microbiol Infect 7, 470–478 (2001).
15. Bercot, B., Poirel, L., Ozdamar, M., Hakko, E., Turkoglu, S., Nordmann, P.: Low
prevalence of 16S methylases among extended-spectrum β-lactamase-producing Entero-
bacteriaceae from a Turkish hospital. J Antimicrob Chemother 65, 797–798 (2010).
16. Yokoyama, K., Doi, Y., Yamane, K., Kurokawa, H., Shibata, N., Shibayama, K., Yagi, T.,
Kato, H., Arakawa, Y.: Acquisition of 16S rRNA methylase gene in Pseudomonas
aeruginosa. Lancet 362, 1888–1893 (2003).
17. Guven Gokmen, T., Nagiyev, T., Meral, M., Onlen, C., Heydari, F., Koksal, F.: NDM-1 and
rmtC-producing Klebsiella pneumoniae isolates in Turkey. Jundishapur J Microbiol 9,
e33990 (2016).
18. Ermertcan, S., Yilmaz, F. F., Tasli, H., Yurtman, A. N., Aydemir, S. S., Hosgor Limoncu,
M.: Investigation of plasmid mediated methylase genes in aminoglycoside resistant Gram
negative bacteria. Türk Mikrobiyol Cem Derg 43, 12–16 (2013).
AMINOGLYCOSIDE RESISTANCE IN MULTIDRUG-RESISTANT ENTEROBACTERIACEAE 335
Acta Microbiologica et Immunologica Hungarica 66, 2019
